Next Article in Journal
Advances in Drug Design Based on the Amino Acid Approach: Taurine Analogues for the Treatment of CNS Diseases
Previous Article in Journal
Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer’s Disease
Previous Article in Special Issue
The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2012, 5(10), 1120-1127; https://doi.org/10.3390/ph5101120

Norethindrone Acetate in the Medical Management of Adenomyosis

1
Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
2
Department of Obstetrics and Gynecology, Kings County Hospital Center, 451 Clarkson Avenue, Brooklyn, NY 11203, USA
3
Scientific Computing Center, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
*
Author to whom correspondence should be addressed.
Received: 8 July 2012 / Revised: 4 October 2012 / Accepted: 15 October 2012 / Published: 22 October 2012
(This article belongs to the Special Issue Hormone Therapy)
View Full-Text   |   Download PDF [182 KB, uploaded 22 October 2012]   |  

Abstract

The role of norethindrone acetate (NA) in the management of adenomyosis was evaluated with a retrospective chart review of 28 premenopausal women between 27–49 years of age presenting with moderate to severe pelvic pain and bleeding. Bleeding and dysmenorrhea scores were analyzed using paired T-tests. There was significant improvement of both dysmenorrhea and bleeding after treatment. Age showed no correlation with dysmenorrhea or bleeding. Low dose NA could be considered an effective, well-tolerated and inexpensive medical alternative to surgery for treating symptomatic adenomyosis. Large multicentric studies may help validate our findings. View Full-Text
Keywords: norethindrone acetate; adenomyosis; dysmenorrhea norethindrone acetate; adenomyosis; dysmenorrhea
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Muneyyirci-Delale, O.; Chandrareddy, A.; Mankame, S.; Osei-Tutu, N.; Gizycki, H. Norethindrone Acetate in the Medical Management of Adenomyosis. Pharmaceuticals 2012, 5, 1120-1127.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top